Cho K G, Hoshino T, Pitts L H, Nomura K, Shimosato Y
Brain Tumor Research Center, University of California School of Medicine, San Francisco.
Cancer. 1988 Aug 1;62(3):512-5. doi: 10.1002/1097-0142(19880801)62:3<512::aid-cncr2820620312>3.0.co;2-j.
Thirteen patients with metastatic brain tumors received an intravenous infusion of bromodeoxyuridine (BUdR) 200 mg/m2 at craniotomy) to label S-phase tumor cells. Excised tumors were stained immunohistochemically for BUdR. The percentage of BUdR-positive cells was calculated to determine the BUdR labeling index (LI) (or fraction of S-phase cells), which provides an estimate of the proliferative potential. Histologically, 11 patients had adenocarcinoma (four well-differentiated, three moderately differentiated, and four poorly differentiated), one had a large cell carcinoma, and one had a small cell carcinoma. All tumors had a BUdR LI greater than 5% (mean, 13.3 +/- 7% standard deviation). Moderately and poorly differentiated adenocarcinomas had a higher LI than well-differentiated adenocarcinomas (median, 15.3% versus 8.2%). These LI values are considerably higher than those reported for primary tumors with comparable histologic features. Thus, metastatic tumors in the brain may grow faster than the primary tumors from which they originate.
13例转移性脑肿瘤患者在开颅手术时接受静脉输注溴脱氧尿苷（BUdR）200mg/m²，以标记处于S期的肿瘤细胞。切除的肿瘤进行BUdR免疫组织化学染色。计算BUdR阳性细胞的百分比以确定BUdR标记指数（LI）（即S期细胞分数），该指数可评估增殖潜能。组织学检查显示，11例为腺癌（4例高分化、3例中分化、4例低分化），1例为大细胞癌，1例为小细胞癌。所有肿瘤的BUdR LI均大于5%（平均为13.3±7%标准差）。中分化和低分化腺癌的LI高于高分化腺癌（中位数分别为15.3%和8.2%）。这些LI值明显高于具有类似组织学特征的原发性肿瘤所报告的值。因此，脑内转移性肿瘤的生长可能比其原发肿瘤更快。
